As a preeminent contract antibody development company, Creative Biolabs offers high-quality in vitro diagnostic (IVD) antibody development services targeting a wide range of biomarkers. Here, we focus on the copeptin marker of liver cirrhosis and coronary artery disease (CAD). We are committed to providing the highest quality of custom services and products at the most reasonable prices.

Introduction of Copeptin Marker

Copeptin, also known as the arginine-vasopressin (AVP)-associated glycopeptides, is a 39-amino acid glycolized glycopeptide with a molecular mass of 5 kDa. Arginine vasopressin (AVP), which plays a key role in many physiologic and pathologic processes, is tightly bound to platelets and also highly unstable in isolated plasma. Therefore, its measurement is difficult and not routinely available. However, studies have shown that activation of AVP system stimulates copeptin secretion into the circulation from the posterior pituitary gland in equimolar amounts with AVP. Hence, copeptin concentrations closely reflect the production of AVP and can be used as surrogate biomarker of AVP secretion.

Mechanisms involved in the poor prognosis of cirrhosis (favoring the occurrence of multiorgan failures) and their related markers Fig.1 Mechanisms involved in the poor prognosis of cirrhosis (favoring the occurrence of multiorgan failures) and their related markers. (Di, 2015)

Copeptin Marker of Liver Cirrhosis

In recent years, copeptin has been used as a prognostic marker in a variety of diseases, such as sepsis, community acquired pneumonia, chronic obstructive pulmonary failure, heart failure and myocardial infarction. As the C-terminal fragment of the vasopressin precursor, copeptin is secreted from the neurohypophysis together with AVP. Importantly, it has been reported that high AVP concentrations occur in cirrhosis patients in response to hemodynamic stimulus due to the existence of effective arterial hypovolemia secondary to splanchnic arterial vasodilation and portal hypertension. Moreover, recent studies have suggested that high copeptin concentrations are associated with cirrhotic patients with a worse outcome. In this case, copetin can be used as a potential marker for the detection of liver cirrhosis.

Copeptin Marker of Coronary Artery Disease

CAD is a primary cause of death and one-third of all deaths in individuals aged >35 in developed countries are induced by CAD. It occurred when the arteries provided blood to heart muscle turn into hardened and narrowed. With developing CAD, the heart muscle can't obtain enough blood or oxygen it requires and finally results in chest pain (angina) or a heart attack. A recent study has demonstrated that fasting plasma concentration of copeptin which presents circulating levels of VAP, independently forecasts development of CAD, total and cardiovascular mortality in a population with an average age of about 70 years. Another research also showed that copeptin enables to predict heart disease and death, especially in patients with diabetes. These results suggested that copeptin and the vasopressin system are prognostic markers and therapeutic targets for heart disease and death.

The left graph shows survival by copeptin median and sodium cut-point of 135 mEq/L, the right shows the receiver operating characteristic for NT-proBNP, copeptin, sodium, and BNP. Fig.2 The left graph shows survival by copeptin median and sodium cut-point of 135 mEq/L, the right shows the receiver operating characteristic for NT-proBNP, copeptin, sodium, and BNP. (Maisel, 2011)

IVD Antibody Development Services for Copeptin Marker

Nowadays, IVD technologies are undergoing rapid development. IVD antibodies have been extensively used as important tools for the diagnosis of diseases and infections. With experienced scientists and advanced technology, Creative Biolabs is able to provide a full range of high-quality IVD antibody development services of copeptin marker. Our high-affinity IVD antibodies will contribute greatly to the success of your projects.

Creative Biolabs has successfully completed numerous IVD antibody generation and development projects for clients across the globe. If you are interested in the service we can provide, please don't hesitate to contact us and get a quote. We will get in touch with you as soon as possible.

References

  1. Di Martino., (2015) "New prognostic markers in liver cirrhosis." World journal of hepatology 7.9: 1244.
  2. Maisel, A. (2011). “Increased 90-day mortality in patients with acute heart failure with elevated copeptin secondary results from the biomarkers in acute heart failure (BACH) study.” Circulation: Heart Failure 4(5), 613-620.


Online Inquiry

Name:
*Phone:
*E-mail Address:
*Service & Products Interested:
Project Description:
*Verification Code:
Please input "biolabs"(case insensitive) as verification code.

Contact Us

USA
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email:

Follow us on:
Copyright ©2011 - 2019 Creative Biolabs.